NCT01734304View on ClinicalTrials.gov

DC Vaccination for Postremission Therapy in AML

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

March 31, 2018

Study Completion Date

September 30, 2018

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

DC vaccination for postremission therapy in AML

Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65

Trial Locations (1)

81377

Hospital of the University of Munich, LMU; Department od Medicine III, Munich

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER

NCT01734304 - DC Vaccination for Postremission Therapy in AML | Biotech Hunter | Biotech Hunter